These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32315234)

  • 1. Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
    Kongpetch S; Jusakul A; Lim JQ; Ng CCY; Chan JY; Rajasegaran V; Lim TH; Lim KH; Choo SP; Dima S; Popescu I; Duda DG; Kukongviriyapan V; Khuntikeo N; Pairojkul C; Rozen SG; Tan P; Teh BT
    JCO Glob Oncol; 2020 Apr; 6():628-638. PubMed ID: 32315234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and transcriptional alterations of cholangiocarcinoma.
    Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
    DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
    J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
    Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk biomarkers for assessment and chemoprevention of liver fluke-associated cholangiocarcinoma.
    Yongvanit P; Pinlaor S; Loilome W
    J Hepatobiliary Pancreat Sci; 2014 May; 21(5):309-15. PubMed ID: 24408859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
    Jusakul A; Cutcutache I; Yong CH; Lim JQ; Huang MN; Padmanabhan N; Nellore V; Kongpetch S; Ng AWT; Ng LM; Choo SP; Myint SS; Thanan R; Nagarajan S; Lim WK; Ng CCY; Boot A; Liu M; Ong CK; Rajasegaran V; Lie S; Lim AST; Lim TH; Tan J; Loh JL; McPherson JR; Khuntikeo N; Bhudhisawasdi V; Yongvanit P; Wongkham S; Totoki Y; Nakamura H; Arai Y; Yamasaki S; Chow PK; Chung AYF; Ooi LLPJ; Lim KH; Dima S; Duda DG; Popescu I; Broet P; Hsieh SY; Yu MC; Scarpa A; Lai J; Luo DX; Carvalho AL; Vettore AL; Rhee H; Park YN; Alexandrov LB; Gordân R; Rozen SG; Shibata T; Pairojkul C; Teh BT; Tan P
    Cancer Discov; 2017 Oct; 7(10):1116-1135. PubMed ID: 28667006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant GLUT1 Expression Is Associated With Carcinogenesis and Progression of Liver Fluke-associated Cholangiocarcinoma.
    Thamrongwaranggoon U; Sangkhamanon S; Seubwai W; Saranaruk P; Cha'on U; Wongkham S
    In Vivo; 2021; 35(1):267-274. PubMed ID: 33402473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholangiocarcinoma.
    Brindley PJ; Bachini M; Ilyas SI; Khan SA; Loukas A; Sirica AE; Teh BT; Wongkham S; Gores GJ
    Nat Rev Dis Primers; 2021 Sep; 7(1):65. PubMed ID: 34504109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma: Association of diabetes mellitus and cholangiocarcinoma.
    Saengboonmee C; Seubwai W; Wongkham C; Wongkham S
    Cancer Epidemiol; 2015 Jun; 39(3):274-8. PubMed ID: 25910864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group.
    Loilome W; Yooyuen S; Namwat N; Sithithaworn P; Puapairoj A; Kano J; Noguchi M; Miwa M; Yongvanit P
    Tumour Biol; 2012 Dec; 33(6):2289-98. PubMed ID: 22922884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
    Kawano S; Kawada MI; Fukushima S; Arai Y; Shibata T; Miyano SW
    Anticancer Res; 2024 Jun; 44(6):2393-2406. PubMed ID: 38821585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
    Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
    J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection.
    Buckarma E; De La Cruz G; Truty M; Nagorney D; Cleary S; Kendrick M; Borad M; Graham RP; Gores G; Smoot R
    HPB (Oxford); 2022 Oct; 24(10):1748-1756. PubMed ID: 35718679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator.
    Silakit R; Loilome W; Yongvanit P; Chusorn P; Techasen A; Boonmars T; Khuntikeo N; Chamadol N; Pairojkul C; Namwat N
    J Hepatobiliary Pancreat Sci; 2014 Dec; 21(12):864-72. PubMed ID: 25131257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of liver fluke infection as risk factor for cholangiocarcinoma.
    Sithithaworn P; Yongvanit P; Duenngai K; Kiatsopit N; Pairojkul C
    J Hepatobiliary Pancreat Sci; 2014 May; 21(5):301-8. PubMed ID: 24408775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.
    Tsujie M; Iwai T; Kubo S; Ura T; Hatano E; Sakai D; Takeda Y; Kaibori M; Kobayashi T; Katanuma A; Katayose Y; Fukase K
    Jpn J Clin Oncol; 2021 May; 51(6):911-917. PubMed ID: 33822966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expected rate of liver fluke-related cholangiocarcinoma in endemic area of liver fluke with antiparasitic drug distribution program for disease control in Thailand.
    Wiwanitkit V
    J Cancer Res Ther; 2022; 18(4):927-930. PubMed ID: 36149142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of molecular genetics in the clinical management of cholangiocarcinoma.
    Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
    ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
    Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
    Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Ilyas SI; Gores GJ
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.